Mounjaro, Wegovy, and Foundayo: Which Weight Loss Medication Works Fastest?

Which medication is fastest?

You are considering weight loss medication and want to know which one will work quickest. The honest answer: at equivalent doses, Mounjaro and Wegovy produce similar weight loss over the same timeframe. Foundayo (orlistat) works differently and more slowly. The "fastest" option for you depends on your health history, how you prefer to take medication, and how your body responds.

This guide compares the three at the evidence level so you can decide with your prescriber which suits your situation.

Quick comparison

Aspect	Mounjaro	Wegovy	Foundayo
Active ingredient	Tirzepatide	Semaglutide	Orlistat
Type	GLP-1 and GIP receptor agonist	GLP-1 receptor agonist	Lipase inhibitor
How taken	Weekly injection	Weekly injection	Tablet three times daily
Typical weight loss (12 weeks)	5-8% of body weight	4-6% of body weight	2-3% of body weight
Time to first effects	2-4 weeks	2-4 weeks	1-2 weeks (mainly appetite unchanged)
Side effects onset	Weeks 1-2	Weeks 1-2	Days 1-3

How Mounjaro works

Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. This means it mimics two natural hormones that regulate appetite and blood sugar.

In clinical trials, patients on Mounjaro lost an average of 21% of their body weight over 68 weeks when combined with lifestyle changes. Weight loss typically accelerates over the first 12 weeks as the dose increases, then continues more gradually. Most people notice reduced appetite within 2 to 4 weeks of starting.

Mounjaro is injected once weekly under the skin. The dose is increased gradually every four weeks to allow your body to adjust. You start at 2.5 mg and may go up to 15 mg depending on tolerance and response.

Who Mounjaro suits

Mounjaro is suitable if you prefer weekly injections, have a BMI of 30 or above (or 27+ with weight-related health conditions), and want a medication with strong clinical evidence for weight loss. It may be particularly helpful if you also have type 2 diabetes, as it improves blood sugar control.

Who it may not suit

Avoid Mounjaro if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis, or severe gastrointestinal disease. If you are pregnant, breastfeeding, or planning pregnancy, speak to your prescriber before starting or continuing treatment.

Side effects and timeline

Most side effects appear in the first 1 to 2 weeks and improve as your body adjusts. The most common are nausea, vomiting, diarrhoea, and constipation. Nausea is usually mild and settles within days to weeks. Appetite suppression is the intended effect, not a side effect.

Less common but serious side effects include pancreatitis (severe abdominal pain), thyroid changes, and gallbladder issues. If you have a history of pancreatitis, thyroid disease, or severe gastrointestinal conditions, discuss this with your prescriber before starting.

How Wegovy works

Wegovy contains semaglutide, a GLP-1 receptor agonist. It works by slowing stomach emptying and signalling fullness to the brain, reducing hunger and food intake.

In clinical trials, patients on Wegovy lost an average of 15% of their body weight over 68 weeks with lifestyle changes. Weight loss is steady but slightly slower than Mounjaro in head-to-head comparisons, though individual variation is large. You typically notice appetite reduction within 2 to 4 weeks.

Wegovy is also a weekly injection. The starting dose is 0.25 mg, increased every week for the first month, then every four weeks up to a maximum of 2.4 mg.

Who Wegovy suits

Wegovy is suitable if you prefer a weekly injection, have a BMI of 30 or above (or 27+ with weight-related conditions), and want a well-established medication with long-term safety data. It may be a good choice if you have tried other weight loss approaches and want a medication with proven efficacy.

Who it may not suit

Do not use Wegovy if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis, or severe gastrointestinal disease. If you are pregnant, breastfeeding, or planning pregnancy, speak to your prescriber before starting or continuing treatment.

Side effects and timeline

Side effects are similar to Mounjaro: nausea, vomiting, diarrhoea, and constipation are most common in weeks 1 to 2 and usually improve. Appetite suppression is expected and desired.

Serious but rare side effects include pancreatitis, thyroid problems, and gallbladder disease. If you have a history of pancreatitis, thyroid conditions, or severe gastrointestinal disease, discuss this with your prescriber.

How Foundayo works

Foundayo (orlistat) is a tablet that works differently from Mounjaro and Wegovy. It blocks the absorption of about 30% of dietary fat in your gut, so less fat is stored as body weight.

In clinical trials, orlistat produces weight loss of 2 to 3% of body weight over 12 weeks, and up to 5 to 6% over a year. This is slower than GLP-1 medications. Orlistat does not reduce appetite; you still need to choose to eat less. It works best alongside calorie reduction and exercise.

Foundayo is taken as a tablet three times daily with meals. It has no systemic side effects because it works only in the gut.

Who Foundayo suits

Foundayo is suitable if you prefer a tablet over injections, want to avoid GLP-1 medications for any reason, or have mild obesity (BMI 27 to 30). It is a good option if you are motivated to change eating habits and want a medication with minimal systemic side effects.

Who it may not suit

Foundayo is not suitable if you have severe malabsorption, chronic pancreatitis, or severe liver disease. It is less effective if you eat a low-fat diet already. If you are pregnant, breastfeeding, or planning pregnancy, speak to your prescriber before starting or continuing treatment.

Side effects and timeline

Foundayo causes gastrointestinal side effects because fat passes through the gut unabsorbed. These include oily spotting, urgency to defecate, and loose stools. These effects start within days and are dose-dependent. They improve if you reduce fat intake.

Serious side effects are rare. If you have a history of severe gastrointestinal disease, speak to your prescriber.

How to choose between them

Clinical suitability comes first. If you have type 2 diabetes, Mounjaro may be preferred because it also improves blood sugar. If you have a history of pancreatitis, thyroid cancer, or severe gastrointestinal disease, speak to your prescriber about which option is safe for you.

Speed of weight loss matters if you have health conditions that improve with weight loss. Mounjaro and Wegovy produce faster results than Foundayo. If you need faster weight loss for medical reasons, a GLP-1 medication is more likely to help.

Lifestyle readiness is important. All three work best with reduced calorie intake and regular movement. If you are not ready to change eating habits, none will work well. Foundayo requires the most active dietary change because it does not suppress appetite.

Injection versus tablet. Some people prefer injections because they are weekly and do not require daily pills. Others prefer tablets. This is a valid practical consideration.

Cost and access. Speak to your prescriber about current pricing and whether you meet NHS or private clinic criteria.

Common questions

How quickly will I see results?

Most people notice reduced appetite within 2 to 4 weeks of starting Mounjaro or Wegovy. Measurable weight loss usually appears by week 4 to 6. Weight loss accelerates as the dose increases over the first 8 to 12 weeks. With Foundayo, you may feel less hungry within days, but weight loss is slower and depends more on dietary change.

Can I switch from one to another?

Yes. If you start Mounjaro and want to switch to Wegovy, or vice versa, your prescriber can help you do this safely. Switching from a GLP-1 injection to Foundayo is also possible. There is usually a short washout period between stopping one and starting another.

What if I do not lose weight on one of them?

Individual response varies. Some people lose more weight, some less. If you are not seeing results after 12 weeks at a stable dose, speak to your prescriber. They may increase the dose, switch medications, or review your diet and activity level.

Do I need to diet and exercise as well?

Yes. These medications work best alongside reduced calorie intake and regular movement. They reduce appetite and help you eat less, but they do not do the work for you. Most weight loss in trials comes from a combination of medication and lifestyle change.

What happens when I stop the medication?

Weight can return if you stop taking the medication and return to previous eating habits. These are not permanent cures. They are tools to help you lose weight and build new habits. Some people stay on them long-term; others use them to reach a goal and then maintain with lifestyle changes alone.

Are these medications safe long-term?

Mounjaro and Wegovy have been used for weight loss for several years and have good long-term safety data. Foundayo has been used for over 20 years. All carry small risks of serious side effects, which your prescriber will screen for. Long-term safety is monitored and discussed at each review.

Can I use these if I have type 2 diabetes?

Yes. Mounjaro and Wegovy are approved for type 2 diabetes and weight loss. Foundayo can be used alongside diabetes medications. If you have type 2 diabetes, speak to your prescriber about which option is best for your blood sugar control as well as weight loss.

How long does it take to reach the full dose?

Mounjaro takes 16 weeks to reach 15 mg (the maximum dose). Wegovy takes 20 weeks to reach 2.4 mg. Foundayo is at full dose from day one. Slower dose escalation reduces side effects and allows your body to adjust.

---